Bio-Techne Corporation
TECH

$11.96 B
Marketcap
$75.27
Share price
Country
$-0.97
Change (1 day)
$85.57
Year High
$61.16
Year Low
Categories

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

marketcap

P/E ratio for Bio-Techne Corporation (TECH)

P/E ratio as of 2024: 67.18

According to Bio-Techne Corporation's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 67.18. At the end of 2023 the company had a P/E ratio of 44.98.

P/E ratio history for Bio-Techne Corporation from 1989 to 2024

PE ratio at the end of each year

Year P/E ratio
2024 67.18
2023 44.98
2022 49.97
2021 124.26
2020 44.00
2019 82.30
2018 44.24
2017 56.74
2016 40.14
2015 33.91
2014 30.78
2013 22.80
2012 24.40
2011 27.54
2010 19.49
2009 22.92
2008 29.25
2007 26.48
2006 27.11
2005 28.02
2004 33.69
2003 27.67
2002 42.59
2001 39.58
2000 99.34
1999 30.55
1998 23.74
1997 26.07
1996 34.18
1995 19.19
1994 18.75
1993 30.73
1992 37.50
1991 33.75
1990 21.87
1989 25.87